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Application of a New Subretinal Injection Device in the Dog
Abstract
The use of a new subretinal injection device (RetinaJect™ Subretinal Cannula, SurModics, Inc., Eden Prairie,
MN) to access the subretinal space in the canine model was evaluated. Subretinal injections were performed
in 33 mongrel dogs between 2 and 52 months of age (median = 9 months). In 5 normal dogs the injection of
150 μl saline or India ink occurred by using a conventional subretinal injection device (CSID) with a 30-gauge
anterior chamber irrigating cannula. The sclera had to be surgically exposed and penetrated before the
subretinal injection with the CSID could occur. After removing the CSID, the conjunctiva over the sclerotomy
site had to be closed. In a second group of 28 dogs [16 normals, 10 RPE65 mutants, and 2 with progressive
rod cone degeneration (prcd)], the 25-gauge needle of the RetinaJect™ was used to penetrate the conjunctiva
and the sclera. Once the tip of the needle was close to the retinal surface, a 39-gauge polyimide cannula was
extended and brought into apposition with the retina for the subsequent subretinal injection of 150 μl saline,
India ink, or adeno-associated virus (AAV). No closure of the conjunctiva was required. The animals were
clinically monitored between 1 and 59 weeks after surgery. From this second group 25 eyes were harvested for
routine histological analysis either immediately after surgery or after a clinical observation time of between 1
and 40 weeks. Both devices provided equally successful access to the subretinal space. The main advantage of
the RetinaJect™ was that no surgical dissection was required; this led to a shorter procedure time and milder
postoperative conjunctival swelling. In summary, the use of the RetinaJect™ can be recommended as an
alternative to the CSID for subretinal injections in dogs.
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The use of a new subretinal injection device (RetinaJectTM Subretinal Cannula, SurModics, Inc., Eden Prairie,
MN) to access the subretinal space in the canine model was evaluated. Subretinal injections were performed
in 33 mongrel dogs between 2 and 52 months of age (median = 9 months). In 5 normal dogs the injection
of 150 µl saline or India ink occurred by using a conventional subretinal injection device (CSID) with a 30-
gauge anterior chamber irrigating cannula. The sclera had to be surgically exposed and penetrated before
the subretinal injection with the CSID could occur. After removing the CSID, the conjunctiva over the
sclerotomy site had to be closed. In a second group of 28 dogs [16 normals, 10 RPE65 mutants, and 2 with
progressive rod cone degeneration (prcd)], the 25-gauge needle of the RetinaJectTM was used to penetrate
the conjunctiva and the sclera. Once the tip of the needle was close to the retinal surface, a 39-gauge
polyimide cannula was extended and brought into apposition with the retina for the subsequent subretinal
injection of 150 µl saline, India ink, or adeno-associated virus (AAV). No closure of the conjunctiva was
required. The animals were clinically monitored between 1 and 59 weeks after surgery. From this second
group 25 eyes were harvested for routine histological analysis either immediately after surgery or after a
clinical observation time of between 1 and 40 weeks. Both devices provided equally successful access to
the subretinal space. The main advantage of the RetinaJectTM was that no surgical dissection was required;
this led to a shorter procedure time and milder postoperative conjunctival swelling. In summary, the use of
the RetinaJectTM can be recommended as an alternative to the CSID for subretinal injections in dogs.
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INTRODUCTION gauge, blunt-tipped cannula for subretinal injections in
dogs (5). Recently, we (S.V. and E.dJ.) developed a new
device (RetinaJectTM Subretinal Cannula, SurModics,Subretinal injections have been used for the applica-
tion of drugs, cells, and gene therapy vectors. In order Inc., Eden Prairie, MN) for subretinal injections that per-
mits more efficient and easier access to the subretinalto reach photoreceptor or retinal pigment epithelial (RPE)
cells with an agent, subretinal application is required (7, space. The purpose of this study was to evaluate the
RetinaJectTM Subretinal Cannula for the subretinal injec-9,13). Successful gene therapy of inherited retinal de-
generations by subretinal injection has been described in tions in dogs. Outcome measures were successful acute
subretinal bleb formation and degree of ocular inflam-various animal models, including the Royal College of
Surgeons (RCS) rat (11,14), the retinal degeneration mation during the first week after surgery.
(rd) mouse (6,8), and the retinal degeneration slow (rds)
mouse (4). Our group, together with other collaborators, MATERIALS AND METHODS
has reported the successful gene replacement therapy in
Animals and Anesthesia
a dog model for Leber congenital amaurosis with an
RPE65 mutation (1,2). All procedures in this study were approved by the
Institutional Animal Care and Use Committee of theVarious techniques and devices have been described
for subretinal injections (5,13). In the past, our group University of Pennsylvania, and were done in accor-
dance with the ARVO Statement for the Use of Animalshas used a custom-built injection device with a small-
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in Ophthalmic and Vision Research. Mongrel dogs be- mg/kg SQ q12 h) and nonsteroidal anti-inflammatories
(carprofen 2 mg/kg PO q12 h) were administered beforetween 2 and 52 months of age (median = 9 months) were
used (Tables 1 and 2). Of the 33 dogs, 21 animals were and continued for 2 days after surgery.
The dogs were premedicated for anesthesia with atro-normal (2 with few retinal folds), 10 dogs were RPE65
mutants, and 2 dogs were affected by progressive rod- pine sulfate (0.02–0.04 mg/kg SQ) and acepromazine
maleate (0.5 mg/kg SQ). Anesthesia was induced withcone degeneration (prcd) (3) (Tables 1 and 2). The ani-
mals were injected subretinally in either one or both eyes. IV thiopental sodium (20–30 mg/kg). The dogs were
intubated, and inhalation anesthesia was maintained withSome of the unilaterally injected dogs were injected in
the contralateral eye 1 week later (Tables 1 and 2). a gas mixture of isoflurane and oxygen on a semiclosed
system. Intravenous fluid (0.9% sodium chloride, 10 ml/Topical anti-inflammatory premedication consisted
of prednisolone acetate 1% and flurbiprofen 0.03% ad- kg/h) was administered during the surgery.
ministered every 30 min during the 2-h time period be-
Preparation of Eye for Subretinal Injectionfore surgery. Mydriasis was achieved with topical trop-
icamide 1%, phenylephrine 10%, and atropine 1%. For The globe was positioned by retrobulbar injection of
0.9% sodium chloride (volume to effect), and by nylonsurvival surgery, systemic antibiotics (amoxicillin 10
Figure 1. Subretinal injection devices. (A) The conventional subretinal injection device (CSID)
consists of a 30-gauge Knolle anterior chamber irrigating cannula connected to a modified plastic
tuberculin syringe, which contains the reagent to be injected and a rubber plunger. This syringe is
connected through flexible extension tubing to a second tuberculin syringe containing 0.9% sodium
chloride (saline). (B) A slider on the RetinaJectTM moves a 39-gauge polyimide cannula within a
25-gauge needle. A syringe with reagent can be connected to the needle hub at the end of the
flexible silicone tubing. Scale bar: 5 cm.
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Table 1. Summary of Subretinal Injections With the CSID
Postoperative
Preexisting Observation
Retinal
Age Weight Disease Clinical
Dog Eye (Months) Sex (kg) Status Agent (Weeks) Histology
L25 right 2 M 6 none saline 0 Y
L25 left saline 0 Y
L26 right 2 M 6 none saline 1 Y
L29 right 2 M 6 none India ink 0 Y
L29 left India ink 0 Y*
BR226 right 4 M 9 none India ink 0 Y
BR226 left India ink 0 Y
BR233 right 7 F 13 none India ink 1 Y
BR233 left saline 0 Y
*Sub-RPE injection.
stay suture (5-0 Ethilon, Ethicon, Somerville, NJ) pore filter before use. The CSID was removed and the
conjunctiva closed in a simple continuous pattern withplaced in the ventral sclera next to the limbus. The eye
was aseptically prepared with 0.5% diluted povidone- polyglactin 910 suture (7-0 Vicryl, Ethicon). When
performed, the lateral canthotomy was closed with nyloniodine solution, and topical proparacaine 0.5% was ap-
plied for additional analgesia. In order to improve access suture (5-0 Ethilon).
to the globe, the palpebral fissure was kept open with a
RetinaJectTM Subretinal Cannulalid speculum, and in smaller dogs, a lateral canthotomy
had to be performed for better access. A surgical micro- The RetinaJectTM is comprised of a 25-gauge needle
scope was brought in position and used for the entire for penetrating the conjunctiva and sclera (Fig. 1B). This
surgery. Aqueous paracentesis with a 30-gauge needle needle is mounted on a hand piece and contains a 39-
was done at the limbus, and 150 µl of aqueous humor gauge polyimide cannula mounted in larger silicone tub-
removed. An ocular Machemer magnifying vitrectomy ing. The polyimide cannula is attached to a slider within
lens (OMVI; Ocular Instruments, Inc., Bellevue, WA) the handpiece, allowing it to be advanced through the
placed on the cornea was used to visualize the retina for 25-gauge needle. A Luer adapter is located at the end of
the subretinal injections. the silicone tubing and allows the connection of a sy-
ringe or other infusion device (Fig. 1B).
Conventional Subretinal Injection Device (CSID) For injection, dissection of the conjunctiva and sclera
was not required. The globe was penetrated with the 25-The CSID is shown in Figure 1A. A 30-gauge Knolle
gauge needle of the RetinaJectTM 6 mm posterior to lim-anterior chamber irrigating cannula was connected to a
bus, and the tip of the needle was brought into proximitymodified plastic tuberculin syringe containing the re-
of the retinal surface. Using the slider in the hand piece,agent to be injected and a rubber plunger. This syringe
the 39-gauge cannula of the RetinaJectTM was extendedwas connected through flexible extension tubing to a
from the tip of the 25-gauge needle and brought tangen-second tuberculin syringe containing 0.9% sodium chlo-
tially into contact with the retina followed by the briskride (saline) and operated by an assistant. The lateral
injection of 150 µl of saline, India ink, or adeno-associ-sclera was exposed, by dissecting the overlying conjunc-
ated virus (AAV) (Table 2). The RetinaJectTM was re-tiva and Tenon’s capsule, and focally cauterized. Both
moved. Except for the lateral canthotomy (if performed)sclera and pars plana were penetrated perpendicularly
no closure was necessary.with a 25-gauge needle, 6 mm posterior to the limbus
(10). The needle was removed and the 30-gauge cannula
Postoperative Managementof the CSID was inserted through the sclerotomy site
into the vitreous. The blunt tip of the cannula was tan- Some dogs were euthanized immediately at the con-
clusion of surgery, and others were recovered and ob-gentially brought into contact with the retina, and 150
µl of either saline or India ink was briskly injected (Ta- served for 1 week or longer after the subretinal injection.
At 1 week some of the unilaterally injected dogs wereble 1). India ink was filtered through a 0.45-µm mini-
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Table 2. Summary of Subretinal Injections With the RetinaJectTM
Postoperative
Preexisting Observation
Retinal
Age Weight Disease Clinical
Dog Eye (Months) Sex (kg) Status Agent (Weeks) Histology
L30 right 5 F 13 none India ink 1 Y
L30 left saline 0 Y
L23 right 2 M 6 none saline 1 Y
L23 left India ink 0 Y*
EM125 right 3 M 11 none saline 0 Y
EM125 left saline 0 Y
EM127 right 3 M 10 none saline 0 Y
EM127 left saline 0 Y
EM128 right 3 F 11 none saline 0 Y
EM128 left saline 0 Y
GS45 right 15 M 20 none AAV5 5 Y
GS45 left AAV5 5 Y
GS46 right 5 M 15 none AAV5 8 Y
GS46 left AAV5 8 Y
GS47 right 5 M 13 none AAV5 8 Y
GS47 left AAV5 8 Y
GS54 right 4 M 9 none AAV5 8 Y
GS54 left AAV5 8 Y
GS55 right 4 M 8 none AAV5 8 Y
GS55 left AAV5 8 Y
GS60 right 4 F 8 none AAV5 2 Y
GS60 left AAV5 2 Y
BR213 right 28 F 17 RPE65 AAV2 40 Y
BR213 left RPE65 AAV2 40 Y
BR225 right 21 M 16 RPE65 AAV2 40 Y
D285 right 16 M 20 retinal folds saline 7 N
D295 right 9 M 20 retinal folds saline 7 N
N237 left 11 M 9 none saline 7 N
N233 left 12 F 9 none saline 7 N
N241 right 11 F 9 none saline 7 N
X192 right 38 M 12 prcd saline 59 N
X197 right 37 F 9 prcd saline 59 N
BR210 right 29 F 23 RPE65 AAV2 44 N
BR210 left RPE65 AAV2 44 N
EMB14 right 23 M 23 RPE65 AAV2 44 N
EMB14 left RPE65 AAV2 44 N
EMB15 right 23 F 18 RPE65 AAV2 44 N
BR230 right 21 F 18 RPE65 AAV2 44 N
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Table 2. Continued
Postoperative
Preexisting Observation
Retinal
Age Weight Disease Clinical
Dog Eye (Months) Sex (kg) Status Agent (Weeks) Histology
BR57 right 52 F 20 RPE65 AAV2 44 N
BR57 left RPE65 AAV2 44 N
EMB62 right 9 F 16 RPE65 AAV2 6 N
EMB62 left RPE65 AAV2 6 N
EMB59 right 9 F 18 RPE65 AAV2 6 N
EMB59 left RPE65 AAV2 6 N
BR303 right 7 F 14 RPE65 AAV2 6 N
BR303 left RPE65 AAV2 6 N
prcd: progressive rod-cone degeneration; RPE65: RPE65 mutant (Leber congenital amaurosis); AAV2, AAV5:
adeno-associated virus type 2 and 5.
*Sub-RPE injection.
anesthetized again for subretinal injection of the contra- the continuation of both systemic amoxicillin and carpro-
fen for 2 days (same dosages as before surgery), and topi-lateral eye and euthanized following the second proce-
dure (Tables 1 and 2). cal prednisolone acetate 1% and atropine 1% were used
for 1 week as needed to control mild postoperative uveitis.In the survival surgery, 5 mg of triamcinolone aceto-
nide was injected subconjunctivally before recovery from
Histologic Evaluationanesthesia, and an antibiotic-steroid ointment (Neomycin-
Polymyxin B-Dexamethasone 0.1% ointment) was used In addition to the clinical evaluation, histologic stud-
ies were performed in 34 eyes of 18 dogs (Tables 1 andtopically. The postoperative medical treatment included
Figure 2. Subretinal blebs as seen through the surgical microscope and the Machemer lens (A), or by indirect ophthalmoscopy (B)
immediately after the injection with the RetinaJectTM. The green reflection represents the tapetal fundus.
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Figure 3. Subretinal bleb seen over the tapetum (T) immediately after saline injection (A, B). Scale bar: 500 µm (A) and 100 µm
(B) [original magnification ×20 (A) and ×200 (B)].
2). These dogs were euthanized with an IV overdose of
sodium pentobarbital. The eyes were enucleated and
fixed either in Bouin solution for paraffin embedding
or in 4% paraformaldehyde solution for embedding in
Optimal Cutting Temperature (OCT) compound. The
globes were processed routinely and sectioned through
the subretinal injection areas. Paraffin sections were
stained with hematoxylin and eosin (H&E).
RESULTS
A total of 9 eyes in 5 dogs were injected with the
CSID while 46 eyes in 28 dogs were injected with the
RetinaJectTM. All 5 dogs treated with the CSID were nor-
mal and were between 2 and 7 months of age (median =
2 months) (Table 1). Using the CSID, 4 eyes were
injected with saline and 5 with India ink. Of these 9
injected eyes, 2 were followed for 1 week and 7 were
harvested immediately after the subretinal injection (Ta-
ble 1). Because the 100% success rate matched our pre-
vious experience on 29 eyes (1), no additional dogs were
injected with the CSID.
Of the 28 dogs injected with the RetinaJectTM, 16 ani-Figure 4. The retina was reattached and without any obvious
mals were considered normal (2 with few retinal folds),pathologic changes 1 week after the subretinal injection of sa-
line. Scale bar: 50 µm (original magnification ×400). 10 were RPE65 mutants, and 2 were affected by prcd.
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Figure 5. In two cases the bleb occurred between the RPE and the tapetum/choroid. The inset shows magnification of the detached
RPE layer. Scale bar: 200 µm (original magnification ×100).
The dogs of the RetinaJectTM group were between 2 and jection devices. No signs of inflammation were visible
1 week postinjection. Histologically, no difference could52 months of age (median = 10 months) (Tab. 2). Using
the RetinaJectTM, saline was injected in 15 eyes, India be observed between the two techniques (Fig. 3).
While limbal-based conjunctival flaps had to be dis-ink in 2 eyes, and AAV in 29 eyes. Of these 46 injected
eyes, 8 were collected immediately after surgery, 2 each sected and then closed in all the eyes in which the CSID
was used, no surgical dissection and closure where re-were removed at 1 and 2 weeks postinjection, and the
remaining 34 eyes were monitored clinically between 5 quired for the application of the RetinaJectTM. This
meant that the surgery time was shorter for the Retinaand 59 weeks (Table 2). Of these latter eyes, 2 were
collected after 5 weeks, 8 after 8 weeks, and 3 after JectTM compared to the CSID; however, surgery times
were not measured quantitatively. The injection of India40 weeks; the remaining eyes are still being monitored
clinically as part of a separate study (Table 2). Except ink with the RetinaJectTM revealed less leakage from the
subretinal bleb into the vitreous than with the CSID.for the technical outcome measures of this study, the
results of the AAV injections will be reported elsewhere. Subjectively, the retinotomy sites appeared smaller after
injection with the RetinaJectTM than with the CSID but
Comparison of RetinaJectTM With CSID this could not be confirmed histologically.
The success rate of the subretinal injections was the
Other Findingssame with both devices. Subretinal blebs were visible in
all eyes immediately after the injection (Fig. 2), and no The injected subretinal fluid was absorbed and the
retinas reattached within 24–48 h. Histologically, thesigns of ocular discomfort were observed in any of the
operated animals. While chemosis was mild in all eyes subretinal blebs were only visible if the eyes were har-
vested immediately after the injection (Fig. 3). Oneafter surgery, the conjunctival swelling appeared less
with RetinaJectTM than with CSID. Clinical signs of ocu- week after the subretinal injection, no signs of subretinal
fluid could be seen clinically or histologically (Fig. 4).lar inflammation were mild and similar for the two in-
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Figure 6. Total retinal degeneration and disorganization 1 week after subretinal injection of India ink. Scale bar: 100 µm (original
magnification ×200).
With each injection device sub-RPE injections were these is the fact that RetinaJectTM allows combining mul-
tiple steps of the surgery. Conjunctiva, Tenon’s capsule,observed histologically in one eye (Tables 1 and 2, Fig.
5). Because the injections were placed in the tapetal re- sclera, and pars plana were penetrated with the 25-gauge
needle, which also protected the sensitive 39-gauge can-gion, where the RPE lacks pigmentation, the difference
between the subretinal and sub-RPE injections could not nula inside. Once the tip of the needle was close to the
retinal surface, the 39-gauge cannula could be extendedbe appreciated, either during surgery or by ophthalmos-
copy after the procedure. with a slider for the subsequent subretinal injection. This
approach was less traumatic, and no closure of surgicalWe noted clinical signs indicating loss of retinal
function (negative menace response, pupillary light re- wounds was required.
The number of eyes injected with the CSID wasflexes, and dazzle reflex) 1 day after the injection of
India ink. Histologic evaluation confirmed the general- smaller than the number injected with the RetinaJectTM.
Because the CSID was previously successfully used forized retinal degeneration (Fig. 6).
29 surgeries on RPE65 mutant eyes (1), and the results
DISCUSSION were identical to the ones listed here, we did not con-
sider it necessary to operate more dogs.This study showed the same effectiveness of subreti-
nal injections in dogs using either the RetinaJectTM or New treatment options for inherited retinal degenera-
tions, such as gene therapy, will soon enter clinicalthe CSID. However, there were advantages when using
the RetinaJectTM compared to the CSID. Chief among trials. For some of these new treatments subretinal injec-
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Kelling, S. E.; Maguire, A. M.; Palczewski, K.; Haus-tions will be required. The RetinaJectTM will simplify
wirth, W. W.; Jacobson, S. G. Long-term restoration ofthis approach, and can be used in either normal or mod-
rod and cone vision by single dose rAAV-mediated gene
erately degenerate retinas. transfer to the retina in a canine model of childhood blind-
Histologically, we found one eye with a sub-RPE ness. Mol. Ther. 12:1072–1082; 2005.
2. Acland, G. M.; Aguirre, G. D.; Ray, J.; Zhang, Q.; Ale-bleb for each injection device. This came as a surprise
man, T. S.; Cideciyan, A. V.; Pearce-Kelling, S. E.;because clinically all the blebs appeared similar. We are
Anand, V.; Zeng, Y.; Maguire, A. M.; Jacobson, S. G.;not aware of any previous reports that described the inci-
Hauswirth, W. W.; Bennett, J. Gene therapy restores vi-dence of sub-RPE blebs with subretinal injections. This sion in a canine model of childhood blindness. Nat. Genet.
observation could only be made when the eyes were har- 28:92–95; 2001.
3. Aguirre, G. D.; Acland, G. M. Variation in retinal degen-vested immediately after the injections. Because the su-
eration phenotype inherited at the prcd locus. Exp. Eyebretinal blebs disappeared within 24–48 h after surgery,
Res. 46:663–687; 1988.a sub-RPE bleb could not be seen at a later time. One 4. Ali, R. R.; Sarra, G. M.; Stephens, C.; Alwis, M. D.; Bain-has to be aware of this phenomenon because it could bridge, J. W.; Munro, P. M.; Fauser, S.; Reichel, M. B.;
explain a potential failure of treatment when therapy is Kinnon, C.; Hunt, D. M.; Bhattacharya, S. S.; Thrasher,
A. J. Restoration of photoreceptor ultrastructure and func-directed specifically to the cells that line the interpho-
tion in retinal degeneration slow mice by gene therapy.toreceptor space. Sub-RPE blebs should be easier recog-
Nat. Genet. 25:306–310; 2000.nized in areas of the fundus with a pigmented RPE. This 5. Bennett, J.; Anand, V.; Acland, G. M.; Maguire, A. M.
would be the case in the nontapetal part of the canine Cross-species comparison of in vivo reporter gene expres-
fundus. Further studies would have to be done to deter- sion after recombinant adeno-associated virus-mediated
retinal transduction. Methods Enzymol. 316:777–789;mine the frequency of sub-RPE blebs with subretinal in-
2000.jections using the RetinaJectTM or CSID.
6. Bennett, J.; Tanabe, T.; Sun, D.; Zeng, Y.; Kjeldbye, H.;While India ink was very useful to evaluate leakage Gouras, P.; Maguire, A. M. Photoreceptor cell rescue infrom the subretinal bleb into the vitreous, its use is not retinal degeneration (rd) mice by in vivo gene therapy.
recommended for survival studies. India ink led to a gen- Nat. Med. 2:649–654; 1996.
7. Dudus, L.; Anand, V.; Acland, G. M.; Chen, S. J.; Wilson,eralized retinal degeneration in our dogs, even in areas
J. M.; Fisher, K. J.; Maguire, A. M.; Bennett, J. Persistentaway from the subretinal bleb. To the best of our knowl-
transgene product in retina, optic nerve and brain after in-edge, retinal toxicity of India ink has not been described
traocular injection of rAAV. Vis. Res. 39:2545–2553;previously. One experimental application of India ink is 1999.
the induction of ocular hypertension in rodents after ante- 8. Kumar-Singh, R.; Farber, D. B. Encapsidated adenovirus
mini-chromosome-mediated delivery of genes to the ret-rior chamber injection followed by laser treatment of the
ina: application to the rescue of photoreceptor degenera-episcleral vessels (12). There are no indications that India
tion. Hum. Mol. Genet. 7:1893–1900; 1998.ink causes any retinal degeneration in these animals. 9. Schraermeyer, U.; Thumann, G.; Luther, T.; Kociok, N.;In summary, the use of RetinaJectTM, a new subretinal Armhold, S.; Kruttwig, K.; Andressen, C.; Addicks, K.;
injection device with 25-gauge needle and extendable Bartz-Schmidt, K. U. Subretinally transplanted embryonic
stem cells rescue photoreceptor cells from degeneration in39-gauge cannula, can be recommended as an alterna-
the RCS rats. Cell Transplant. 10:673–680; 2001.tive to the CSID for subretinal injections in dogs.
10. Smith, P. J.; Pennea, L.; MacKay, E. O.; Mames, R. N.
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